Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Free Cash Flow · Q4 FY2025 · quarter ended Dec 2025
Free cash flow turns negative
Q4 FY2025 free cash flow was -CN¥787.41M, compared with CN¥235.27M a year earlier. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Free cash flow amounted to 215.2% of revenue in FY2025, up 201.3 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
CNY · from the cash flow
- Latest · FY2025
- (1.2B) CNY
- Year-over-year change
- -785.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.2B) | -785.9% |
| FY2024 | 2024-12-31 | (135.65M) | +82.7% |
| FY2023 | 2023-12-31 | (782.92M) | +12.1% |
| FY2022 | 2022-12-31 | (890.88M) | +14.4% |
| FY2021 | 2021-12-31 | (1.04B) | — |
Free Cash Flow vs competitors
How AAPG compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +785.9% is the highest of 10, against a peer median of +2.5%.
- Free cash flow amounts to 215.2% of revenue for AAPG, versus a peer median of 52.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.2B CNY | +785.9% | +10.5% | 215.2% |
| LTM Aug 2026 | $369.81M USD | +253.2% | +15.3% | 52.7% | |
| LTM Jun 2026 | $162.52M USD | -28.5% | -25.2% | 36.1% | |
| LTM Mar 2026 | $152.29M USD | +32.3% | +29.3% | 307.1% | |
| LTM Sep 2026 | $150.39M USD | +2.5% | +6.2% | — | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $96.02M USD | +19.3% | -3.8% | 275.4% | |
| LTM Mar 2026 | $87.93M USD | -67.2% | -6.8% | 39.0% | |
| LTM Jun 2026 | $82.72M USD | -50.9% | +21.7% | 48.7% | |
| LTM Jun 2024 | $66.94M USD | — | -8.8% | 1031.4% | |
| LTM Mar 2026 | $49.91M USD | -7.0% | +0.5% | — | |
| Peer median (excluding AAPG) | — | +2.5% | +3.3% | 52.7% | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.24B) |
| Depreciation & Amortization | 28.33M | 62.92M | 93.2M | 93.17M | 86.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.97M | 22.11M | 31.5M | 20.92M | 20.87M |
| Change in Working Capital | (74.91M) | 104.41M | (9.15M) | 110.97M | (143.5M) |
| Accounts Receivables | (53.97M) | (388K) | (91.54M) | 62.75M | (169.8M) |
| Inventory | (3.93M) | (5.52M) | (6.72M) | 9.57M | (26.2M) |
| Accounts Payables | 0 | 24.7M | (23.11M) | 19.52M | 14.77M |
| Other Working Capital | (17.01M) | 85.62M | 112.22M | 19.13M | 37.72M |
| Other Non-Cash Items | 227.18M | 43.82M | 91.23M | 58.84M | 98.07M |
| Operating Cash Flow | (604.68M) | (653.92M) | (726.08M) | (111.36M) | (1.17B) |
| Capital Expenditures | (436.63M) | (236.96M) | (56.84M) | (24.29M) | (27.57M) |
| Acquisitions (Net) | (36.2M) | (20M) | (20M) | (25.52M) | (43.34M) |
| Purchases of Investments | (1.78B) | (130M) | 0 | (312.23M) | (929.14M) |
| Sales of Investments | 1.79B | 0 | 0 | 0 | 0 |
| Other Investing Activities | (879K) | (31.32M) | 88.03M | (312.23M) | 0 |
| Investing Cash Flow | (466.52M) | (384.61M) | 21.92M | (362.04M) | (1B) |
| Debt Repayment | 548.59M | 695.87M | (13.36M) | (145.34M) | 307.26M |
| Common Stock Issued | 1.3B | 0 | 470.08M | 533.94M | 2.3B |
| Common Stock Repurchased | (25.87M) | (26.78M) | (5.92M) | 0 | (9.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (41.97M) | (49.83M) | (82.05M) | (73.83M) | (63.04M) |
| Financing Cash Flow | 1.78B | 619.27M | 368.75M | 314.77M | 2.54B |
| Effect of Forex Changes | (23.28M) | 58.01M | 27.81M | 13.68M | (63.24M) |
| Net Change in Cash | 686.91M | (361.25M) | (307.59M) | (144.95M) | 302.68M |
| Free Cash Flow | (1.04B) | (890.88M) | (782.92M) | (135.65M) | (1.2B) |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.